U.S. markets closed

Galecto, Inc. (GLTO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.9500+0.2100 (+4.43%)
At close: 4:00PM EDT
4.9300 -0.02 (-0.40%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close4.7400
Open4.6900
Bid4.8900 x 1200
Ask4.9300 x 900
Day's Range4.6300 - 5.0500
52 Week Range4.5020 - 17.9900
Volume3,987,562
Avg. Volume989,011
Market Cap125.046M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Galecto's GB0139 Shows Favorable Safety In COVID-19 Patients, But Plans To Focus On Fibrosis, Cancer Programs
    Benzinga

    Galecto's GB0139 Shows Favorable Safety In COVID-19 Patients, But Plans To Focus On Fibrosis, Cancer Programs

    Amid the continued evolution of the COVID-19 landscape, Galecto Inc (NASDAQ: GLTO) said it would focus on the Phase 2 pipeline of fibrosis and cancer treatments, despite announcing positive preliminary topline results from an investigator-initiated trial examining GB0139 in COVID-19. The trial included 41 hospitalized patients who did not require mechanical ventilation, of which 20 were randomized to the GB0139 arm. GB0139 showed a favorable safety profile with no treatment-related serious adver

  • Galecto’s GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients
    GlobeNewswire

    Galecto’s GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients

    GB0139 significantly reduced oxygen flow requirements and improved several biomarkers for lung and systemic inflammation, liver function, tissue damage and coagulationData demonstrate potential of GB0139 in patients with viral-induced acute lung injuryCurrently Galecto will prioritize resources for its four phase 2 trials in fibrosis and cancer BOSTON and COPENHAGEN, Denmark, June 22, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed, clinical stage biotechnology company f

  • Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times
    MarketWatch

    Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times

    Shares of Orphazyme A/S blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that